文献速递免疫规划传染病防控与疫情报告

青少年期乙型肝炎病毒疫苗加强接种降低高危成人HBV感染

Adolescent booster with hepatitis B virus vaccines decreases HBV infection in high-risk adults.
PubMed 文献 · Vaccine · 2017-01-06

在「启东乙型肝炎干预研究」疫苗接种组中纳入9793名童年期HBsAg阴性且童年与成年均献血者,其中7414人在10-14岁接种一剂10μg重组HBV疫苗加强针;至23-28岁,母亲HBsAg阳性者成年期慢性HBV感染风险显著升高(校正OR 12.56,95%CI 7.14-22.08),青少年期加强接种对高危成人有显著保护(趋势P=0.015)。

要点

  • 母亲HBsAg阳性是疫苗接种保护儿童成年期发生HBV突破感染的独立危险因素。
  • 10-11岁时抗-HBs阴性显著增加高危成人HBV感染风险。
  • 一剂青少年期加强针对高危成人慢性HBV感染有显著保护,趋势P=0.015。

核心结论

  • 母亲HBsAg阳性状态是疫苗接种保护儿童成年期发生HBV突破感染的独立危险因素。
  • 青少年期加强接种可能适用于母亲HBsAg阳性且血清抗-HBs<10mIU/ml的高危个体。

研究设计与样本

  • 研究纳入「启东乙型肝炎干预研究」疫苗接种组中9793名童年期HBsAg阴性且童年与成年均献血者。
  • 其中7414人在10-14岁接种一剂10μg重组HBV疫苗加强针。
  • 终点(23-28岁)检测HBV血清学标志物并定量慢性HBV感染成人的血清HBV-DNA。

主要发现

  • 57名成人被确定为慢性HBV感染,表现为HBsAg(+)且抗-HBc(+)持续超过6个月。
  • 母亲HBsAg阳性者(高危成人)较母亲HBsAg阴性者成年期慢性HBV感染风险显著升高,校正OR为12.56(95%CI 7.14-22.08)。
  • 10-11岁时抗-HBs阴性显著增加高危成人HBV感染风险。
  • 母亲HBsAg阳性且HBsAg(-)&抗-HBc(+)的儿童中,70%维持该状态,10%发展为HBsAg(+)&抗-HBc(+);母亲HBsAg阴性者中,1.05%的HBsAg(-)&抗-HBc(+)儿童发展为HBsAg(+)&抗-HBc(+),24.74%维持该状态,随访12-18年。
  • 一剂青少年期加强针对高危成人慢性HBV感染显示显著保护,趋势P=0.015。

关键数值与推荐

  • 慢性HBV感染定义为HBsAg(+)且抗-HBc(+)持续超过6个月。
  • 高危成人定义为母亲HBsAg阳性者,其成年期慢性HBV感染校正OR为12.56(95%CI 7.14-22.08)。
  • 青少年期加强接种方案为一剂10μg重组HBV疫苗,接种年龄10-14岁。
  • 加强接种保护效应的趋势检验P=0.015。

临床怎么用

  • 作者认为,青少年期加强接种可能适用于母亲HBsAg阳性且血清抗-HBs<10mIU/ml的高危个体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neutralizing antibodies (anti-HBs) after immunization with hepatitis B virus (HBV) vaccines against HBV surface antigen (HBsAg) wane after 10-15years. We analyzed the effect of an adolescent booster given to vaccination-protected children born to mothers with different HBsAg-carrying status against HBV infection in their mature adulthood. METHODS: A total of 9793 individuals, who were HBsAg-negative at childhood (baseline) and donated blood samples, both during childhood and adulthood, from the vaccination group in "Qidong Hepatitis B Intervention Study", were enrolled. Among them 7414 received a one-dose, 10μg-recombinant HBV vaccine booster at 10-14years of age. At endpoint (23-28years of age), we determined the HBV serological markers and quantified their serum HBV-DNA in each of the chronic HBV-infected adults. RESULTS: Fifty-seven adults were identified as chronic HBV infection, indicated by HBsAg(+)&anti-HBc(+) for more than 6months. The individuals who were born to HBsAg-positive mothers (high-risk adults) had significantly increased risk of developing chronic HBV infections in adulthood compared with those who were born to HBsAg-negative mothers; the adjusted odds ratio (OR) was 12.56, 95%CI:7.14-22.08. The seronegative status of anti-HBs at 10-11years of age significantly increased the risk of HBV infections among the high-risk adults. When HBsAg(-)&anti-HBc(+) children who were born to HBsAg-positive mothers 70% of them remained as the status and 10% of them developed HBsAg(+)&anti-HBc(+). While when they were born to HBsAg-negative mothers 1.05% HBsAg(-)&anti-HBc(+) children developed HBsAg(+)&anti-HBc(+) and 24.74% of them remained as the status in 12-18years. One dose of adolescent booster showed significant protection on high-risk adults from chronic HBV infection; P for trend was 0.015. CONCLUSIONS: Maternal HBsAg-positive status was an independent risk factor for vaccination-protected children to develop HBV breakthrough infection in adulthood. Adolescent boosters might be appropriate for high-risk individuals who were born to HBsAg-positive mothers when their serum anti-HBs<10mIU/ml.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wang Y, Chen T, Lu LL, et al. Adolescent booster with hepatitis B virus vaccines decreases HBV infection in high-risk adults. Vaccine. 2017. PMID: 28069363. doi:10.1016/j.vaccine.2016.12.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。